|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-7-31
|
|
pubmed:abstractText |
In vitro data indicate that biotransformation of the synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor fluvastatin is catalyzed by the cytochrome P450 (CYP) enzyme 2C9. The consequences of CYP2C9 genetic polymorphisms on fluvastatin pharmacokinetics and on its efficacy have not been investigated in humans thus far.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/CYP2C9 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Monounsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/cerivastatin,
http://linkedlifedata.com/resource/pubmed/chemical/fluvastatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
74
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
186-94
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12891229-Adult,
pubmed-meshheading:12891229-Amino Acid Substitution,
pubmed-meshheading:12891229-Anticholesteremic Agents,
pubmed-meshheading:12891229-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:12891229-Cholesterol,
pubmed-meshheading:12891229-Cholesterol, HDL,
pubmed-meshheading:12891229-Cholesterol, LDL,
pubmed-meshheading:12891229-DNA, Complementary,
pubmed-meshheading:12891229-Fatty Acids, Monounsaturated,
pubmed-meshheading:12891229-Female,
pubmed-meshheading:12891229-Genotype,
pubmed-meshheading:12891229-Humans,
pubmed-meshheading:12891229-Indoles,
pubmed-meshheading:12891229-Male,
pubmed-meshheading:12891229-Middle Aged,
pubmed-meshheading:12891229-Polymorphism, Genetic,
pubmed-meshheading:12891229-Pyridines,
pubmed-meshheading:12891229-Stereoisomerism,
pubmed-meshheading:12891229-Triglycerides
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
|
|
pubmed:affiliation |
Institute of Clinical Pharmacology, Charité, Humboldt University of Berlin, Berlin, Germany. julia.kirchheiner@charite.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
